Antibiotic Therapy Practices for Ventilator-Associated Pneumonia (PETUNIA)

Survey on Antibiotic Therapy Practices for Ventilator-Associated Pneumonia in ICU Patients

The French Society of Intensive Care conducts a comprehensive assessment of current antibiotic therapy practices in critically ill patients suspected of Ventilator-Associated Pneumonia (VAP).

This prospective observational multicenter study will be conducted in intensive care units (ICU) across France and French-speaking regions. The primary objective of this study is to delineate the characteristics of antibiotic treatments administered for a first episode of suspected VAP. Secondary objectives include describing the outcomes of enrolled patients, assessing adherence to European guidelines regarding empirical antibiotic treatment, and identifying factors associated with mortality in patients with microbiologically confirmed VAP.

Inclusion Criteria:

• Age ≥ 18 years
• Admission to the ICU
• Intubation and duration of invasive mechanical ventilation > 48 hours
• Initiation of new antibiotic therapy to treat a first suspicion of Ventilator-Associated Pneumonia (VAP)

Exclusion Criteria:

• Presence of a decision to limit active therapeutic measures at the time of initiating antibiotic therapy
• Organ donor
• Prior inclusion in the study during a previous stay in the intensive care unit (a patient cannot be included multiple times)
• Participation in an interventional study focusing on the management of VAP and directly impacting antibiotic therapy practices
• Patient and/or family opposition to participation
• Lack of affiliation with a social security system